ARE Patent Law Alert:
IN SAS INSTITUTE INC. V. IANCU, U.S. SUPREME COURT DETERMINES THAT PTAB MUST ISSUE A FINAL WRITTEN DECISION ADDRESSING ALL CHALLENGED CLAIMS IN IPR PROCEEDINGS

On April 24, 2018, the Supreme Court of the United States issued a 5-4 opinion in SAS Institute Inc. v. Iancu, No. 16-969, 584 U.S. ____ (2018). In this Decision, the Court reversed the decision of the United States Court of Appeals for the Federal Circuit (“Federal Circuit”) and held that “the petitioner in an inter […]

Patent Law Alert:PTAB ISSUES A GUIDANCE ON MOTIONS TO AMEND IN VIEW OF FEDERAL CIRCUIT’S AQUA PRODUCTS DECISION

On November 22, 2017, the Patent Trial and Appeal Board (“PTAB”) issued a guidance on motions to amend filed in inter partes review (“IPR”) and post-grant review (“PGR”) proceedings following the Federal Circuit’s en banc decision in Aqua Products, Inc. v. Matal, 872 F.3d 1290 (Fed. Cir. 2017) (https://www.uspto.gov/sites/default/files/documents/guidance_on_motions_to_amend_11_2017.pdf?utm_campaign=subscriptioncenter&utm_content=&utm_medium=email&utm_name=&utm_source=govdelivery&utm_term=) (“the Guidance”). In the Guidance, the […]

Exploring Viability Of ‘Diagnose And Treat’ Method Claims

Law360’s Expert Analysis Exploring Viability Of ‘Diagnose And Treat’ Method Claims The enforceability of single claims that cover the steps of both diagnosing and treating a patient is discussed in view of Cleveland Clinic Foundationv. True Health Diagnostics LLC[1], which held that the claims in U.S. Patent No. 9,170,260[2] were not infringed under either contributory infringement or […]